Ceftriaxone for the Treatment of Chronic Bacterial Prostatitis: A Case Series and Literature Review

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2022 Jan 21

PMID 35052960

Authors

Sander G Kuiper

Maarten Ploeger

Erik B Wilms

Marleen M van Dijk

Emiel Leegwater

Robert A G Huis Int Veld

Cees Van Nieuwkoop

Affiliations

Soon will be listed here.

Abstract

Chronic bacterial prostatitis is increasingly difficult to treat due to rising antimicrobial resistance limiting oral treatment options. In this case series, 11 men with CBP (including patients with urological comorbidities) due to multi-resistant were treated with once-daily ceftriaxone intravenously for 6 weeks. Nine patients were clinically cured at 3 months follow up. No early withdrawal of medication due to side effects occurred. A literature review was conducted to describe the prostate pharmacokinetics of ceftriaxone and its use in prostatic infection. In conclusion, ceftriaxone can be considered an appropriate treatment of chronic bacterial prostatitis.

Citing Articles

A combined electrohydrodynamic atomization method for preparing nanofiber/microparticle hybrid medicines.

Sun L, Zhou J, Chen Y, Yu D, Liu P Front Bioeng Biotechnol. 2023; 11:1308004.

PMID: 38033817 PMC: 10684662. DOI: 10.3389/fbioe.2023.1308004.

References

van Driel A, Notermans D, Meima A, Mulder M, Donker G, Stobberingh E . Antibiotic resistance of Escherichia coli isolated from uncomplicated UTI in general practice patients over a 10-year period. Eur J Clin Microbiol Infect Dis. 2019; 38(11):2151-2158. PMC: 6800841. DOI: 10.1007/s10096-019-03655-3. View

Wilson M, Gaido L . Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. 2004; 38(8):1150-8. DOI: 10.1086/383029. View

Erb S, Frei R, Tschudin Sutter S, Egli A, Dangel M, Bonkat G . Basic patient characteristics predict antimicrobial resistance in E. coli from urinary tract specimens: a retrospective cohort analysis of 5246 urine samples. Swiss Med Wkly. 2018; 148:w14660. DOI: 10.4414/smw.2018.14660. View

Dalhoff A . Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis. 2012; 2012:976273. PMC: 3477668. DOI: 10.1155/2012/976273. View

Wijnakker R, Visser L, Schippers E, Visser L, van Burgel N, Van Nieuwkoop C . The impact of an infectious disease expert team on outpatient parenteral antimicrobial treatment in the Netherlands. Int J Clin Pharm. 2018; 41(1):49-55. PMC: 6394504. DOI: 10.1007/s11096-018-0751-4. View

Rubin R, Shapiro E, Andriole V, Davis R, Stamm W . Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992; 15 Suppl 1:S216-27. DOI: 10.1093/clind/15.supplement_1.s216. View

Raz R, Almog D, Elhanan G, Shental J . The use of ceftriaxone in the prevention of urinary tract infection in patients undergoing transurethral resection of the prostate (TUR-P). Infection. 1994; 22(5):347-9. DOI: 10.1007/BF01715544. View

Naber K . Management of bacterial prostatitis: what's new?. BJU Int. 2008; 101 Suppl 3:7-10. DOI: 10.1111/j.1464-410X.2008.07495.x. View

Simmons M, Neeb A, Johnson-Mitchell M . Reduced Risk of Sepsis after Prostate Biopsy Using a Cephalosporin-Fluoroquinolone Antibiotic Regimen and Isopropyl Alcohol Needle Washing. Urology. 2018; 115:102-106. DOI: 10.1016/j.urology.2018.02.012. View

10.

Karaiskos I, Galani L, Sakka V, Gkoufa A, Sopilidis O, Chalikopoulos D . Oral fosfomycin for the treatment of chronic bacterial prostatitis. J Antimicrob Chemother. 2019; 74(5):1430-1437. PMC: 6477975. DOI: 10.1093/jac/dkz015. View

11.

Duncan C, Barr D, Seaton R . Outpatient parenteral antimicrobial therapy with ceftriaxone, a review. Int J Clin Pharm. 2012; 34(3):410-7. DOI: 10.1007/s11096-012-9637-z. View

12.

Zegarra Montes L, Sanchez Mejia A, Loza Munarriz C, Gutierrez E . Semen and urine culture in the diagnosis of chronic bacterial prostatitis. Int Braz J Urol. 2008; 34(1):30-7, discussion 38-40. DOI: 10.1590/s1677-55382008000100006. View

13.

Hammarlund-Udenaes M . Microdialysis as an Important Technique in Systems Pharmacology-a Historical and Methodological Review. AAPS J. 2017; 19(5):1294-1303. DOI: 10.1208/s12248-017-0108-2. View

14.

Barza M . Anatomical barriers for antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1993; 12 Suppl 1:S31-5. DOI: 10.1007/BF02389875. View

15.

Adam D, Naber K . Concentrations of ceftriaxone in prostate adenoma tissue. Chemotherapy. 1984; 30(1):1-6. DOI: 10.1159/000238237. View

16.

Los-Arcos I, Pigrau C, Rodriguez-Pardo D, Fernandez-Hidalgo N, Andreu A, Larrosa N . Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis. Antimicrob Agents Chemother. 2015; 60(3):1854-8. PMC: 4776017. DOI: 10.1128/AAC.02611-15. View

17.

Luong B, Danforth T, Visnjevac O, Suraf M, Duff M, Chevli K . Reduction in hospital admissions with the addition of prophylactic intramuscular ceftriaxone before transrectal ultrasonography-guided prostate biopsies. Urology. 2015; 85(3):511-6. DOI: 10.1016/j.urology.2014.10.047. View

18.

Lipsky B, Byren I, Hoey C . Treatment of bacterial prostatitis. Clin Infect Dis. 2010; 50(12):1641-52. DOI: 10.1086/652861. View

19.

Critchley I, Cotroneo N, Pucci M, Mendes R . The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS One. 2019; 14(12):e0220265. PMC: 6903708. DOI: 10.1371/journal.pone.0220265. View

20.

Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N . Penetration of antimicrobial agents into the prostate. Chemotherapy. 2003; 49(6):269-79. DOI: 10.1159/000074526. View